



Olivia Yip

+1 510-282-7135 | oliviayipwc@gmail.com | [oliviayipwc](https://www.linkedin.com/in/oliviayipwc)

Health economist supporting US and global evidence generation across the product lifecycle in neuroscience. Background in real-world evidence, patient-centered outcomes research, and health economic modeling to develop comprehensive, decision-relevant evidence packages. Proven ability to translate clinical, economic, and humanistic data into differentiated value narratives that inform strategic decision-making.

Education

University of Washington (UW), The CHOICE Institute MS, HEALTH ECONOMICS AND OUTCOMES RESEARCH (HEOR)	2025
University of California, San Diego (UCSD) DOCTOR OF PHARMACY (PHARM D)	2024
University of California, Los Angeles (UCLA) BS, BIOCHEMISTRY	2019

Relevant Experience

Research Fellow, Global HEOR Strategy, Parkinson’s Disease (PD) AbbVie, Inc
 MANAGERS: JAE LEE, PHARM D, MS | JAEHYUN.LEE@ABBVIE.COM; CONNIE YAN, PHARM D, PH D | CONNIE.YAN@ABBVIE.COM July 2024 – Present

- Strengthen **real-world differentiation** and enable evidence-driven decisions to **optimize post-launch access** for Vyalev
 - Direct **patient profiling studies** in collaboration with cross-functional partners to generate strategic insights into target patient populations, provider characteristics, and treatment patterns to **ensure access to the appropriate target population**
 - Lead comparative real-world evidence studies assessing **health outcomes, healthcare resource utilization, and costs** versus standard of care and competitors using open and closed claims and survey data sources, including but not limited to **Adelphi, MarketScan, Optum, and IQVIA**
 - Execute a **systematic literature review (SLR)** to evaluate the impact of restrictive utilization management policies on access, outcomes, healthcare utilization, and costs to **inform payer strategy**
 - Lead **economic modeling** study quantifying the **clinical, economic, societal, and humanistic impact** of delayed treatment initiation, demonstrating the value of earlier intervention by prioritizing clinically meaningful outcomes and long-term cost offsets
- Advance **pre-launch evidence generation** for tavapadon to **address evidence gaps and inform market access strategy** prior to regulatory approval and commercialization
 - Lead the **development of health-state utility values** using time trade-off (TTO) methodologies, partnering with patient advocacy groups and cross-functional stakeholders to generate robust patient-centered evidence that **informs value assessment and HTA submissions** and enhances payer value messaging
 - Drive the development of severity-stratified **incidence and prevalence estimates** through external clinicians and KOL collaboration to inform budget impact model and support **dossier submission**
 - Contribute to **clinical outcome assessments (COA), including gap analyses and comparative evaluations**, to inform outcomes and endpoint strategy for clinical trials and observational study design
 - Support **psychometric evaluations and responder analyses** to define Meaningful Score Differences (MSDs) and Meaningful Score Regions (MSRs), **strengthening interpretation of clinical trial outcomes** and informing commercial, medical, and payer messaging on the clinical meaningfulness of key efficacy endpoints

Research Fellow, HEOR Strategy UW CHOICE
 ADVISOR: KYUEUN LEE, PH D | KYUEUNL@UW.EDU July 2024 – Present

- Conduct a retrospective cohort study using MarketScan to assess **healthcare resource utilization and costs** associated with depression among people with Alzheimer’s disease (AD) to **characterize disease burden and highlight unmet need**
- Perform a **systematic literature review (SLR)** on the prevalence of depression, anxiety, and apathy in AD to **identify key mental health comorbidities and gaps in care**
- Develop a **cost-utility model** evaluating behind-the-counter oseltamivir for influenza treatment from the healthcare sector and modified societal perspectives in high-risk and general populations to **demonstrate the value of broader access**

Affiliate Faculty, Clinical Pharmacy

University of California, San Diego

DEPARTMENT CHAIR: LINDA AWDISHU, PHARM.D, MAS | LAWWDISHU@HEALTH.UCSD.EDU

July 2025 – Present

- Lead multiple research initiatives, including a **distributional cost-effectiveness analysis** of naloxone distribution to **assess equity implications and inform resource allocation**
- **Deliver lectures, lead case-based discussions, and facilitate journal clubs** to strengthen students' understanding of managed care, health economics, and evidence-based decision-making
- Mentor students on database-driven research projects evaluating disease burden, quality of life, and healthcare costs, providing **guidance on study design, analysis, and professional development**

Market Access Extern

Xcenda (Cencora)

MANAGER: CANDACE ZHENG, PHARM.D, BCPS | CANDACE.ZHENG@CENCORA.COM

Nov. 2023 – Dec. 2023

- Evaluated the current and future **oncology competitive landscape**, including product lifecycles, approval timelines, regulatory milestones, and development progress
- Conducted a **targeted literature review** of peer-reviewed publications on **omnichannel marketing**
- Supported **business development** by evaluating company leadership, therapeutic focus, portfolio composition, and pipeline assets

HEOR Extern

University of California, Irvine

ADVISOR: ARYANA SEPASSI, PHARM.D | A1SEPASSI@HEALTH.UCSD.EDU

July 2023 – Aug. 2023

- Conducted **retrospective analysis** using administrative claims to assess disparities in healthcare expenditures and resource utilization **between cancer and non-cancer populations**
- Identified **variations in healthcare spending and resource use** by nativity status and **develop recommendations to address disparities**
- Presented findings to the research team and author a manuscript to **inform subsequent study design**

Manuscripts

Yip O, Sepaasi A. *An evaluation of health care expenditures and resource utilization in patients with cancer using the United States Medical Expenditure Panel Survey*. Journal of Pharmaceutical Health Services Research. (Submitted)

Yip O, Lee K. *Cost-Utility Analysis of Non-Prescription Oseltamivir for Influenza Treatment: U.S. Healthcare Sector and Limited Societal Perspective*. The Journal of Infectious Diseases. (In Preparation)

Yip O, Lee K. *Healthcare Resource Utilization and Costs Associated with Depression Among People with Alzheimer's Disease - A Retrospective Cohort Study*. Journal of Managed Care & Specialty Pharmacy. (Submitted)

Yip O, Bounthavong M (2025). *Enhancing Naloxone Distribution for Opioid Users in the USA: A Cost-Utility Analysis of Academic Detailing to Clinicians*. Applied Health Economics and Health Policy. [Link](#)

Le BH, Phung KC, **Yip O**, Gupta A, Phan LT, Lai H, Hoang L, Nguyen TH, Nguyen DT, Vu HM, Nguyen HLT, and Le J (2024). *Model-Informed Precision Dosing of Vancomycin in Vietnamese Children: Innovative Midpoint Concentration Monitoring Using Two Bayesian Programs*. Therapeutic Drug Monitoring. [Link](#)

Bounthavong M, **Yip O** (2024). *Association Between County-Level Social Vulnerability and Deprivation with Opioid Dispensing Rates in the United States*. International Journal of Mental Health and Addiction. [Link](#)

Yip O, Du E, Morello CM, Bounthavong M (2024). *Comparison between in-person, telehealth, and combination visits among veterans treated in a pharmacist-led diabetes management clinic*. Journal of the American Pharmacists Association. [Link](#)

Poster Presentations

Yip O, Dong A, Li M, Hendrix N, Yousif Z, Bounthavong M. *Health Equity Impact of Academic Detailing on Naloxone Distribution in the United States: An Aggregate Distributional Cost-Effectiveness Analysis*. Submitted to: ISPOR—The Professional Society for Health Economics and Outcomes Research Annual Meeting. 2026 May; Philadelphia, PA.

Yip O, Lee K. *Healthcare Resource Utilization and Costs Associated with Depression Among People with Alzheimer's Disease - A Retrospective Cohort Study*. Accepted at: Academy of Managed Care Pharmacy (AMCP). 2026 March; Nashville, TN.

Nguyen H, Chan J, Pan S, **Yip O**, Morello C, Bounthavong M. *Impact of SGLT2i and GLP-1 RA Use on Productivity Loss and Veterans Rand-12 (VR-12) Physical and Mental Health in U.S. Adults with Type 2 Diabetes Using Pooled Data from the Medical Expenditure Panel Survey (2018 to 2023)*. Presented at: UCSD Summer Research Program Symposium. 2026 January; San Diego, CA. [Link](#)

Yip O, Lee K. *Cost-Utility Analysis of Non-Prescription Oseltamivir for Influenza Treatment: U.S. Healthcare Sector and Limited Societal Perspective (Encore)*. Presented at: EPIDEMICS 10: 10th International Conference on Infectious Disease Dynamics. 2025 December; San Diego, CA. [Link](#)

Yip O, Lee K. *Cost-Utility Analysis of Non-Prescription Oseltamivir for Influenza Treatment: U.S. Healthcare Sector and Limited Societal Perspective*. Presented at: ISPOR—The Professional Society for Health Economics and Outcomes Research Annual Meeting. 2025 May; Montreal, Canada. [Link](#)

Yip O, Sepassi A. *Evaluation of Healthcare Expenditures and Resource Utilization in People with Cancer*. Presented at: Western PharmacoEconomics Conference (WPEC). 2025 March; Seattle, WA. [Link](#)

Yip O, Lee K. *Cost-Utility Analysis of Non-Prescription Oseltamivir for Influenza Treatment: U.S. Healthcare Sector Perspective*. Presented at: Western PharmacoEconomics Conference (WPEC). 2025 March; Seattle, WA. [Link](#)

Yip O, Lee J, Lee K. *Prevalence of Depression, Anxiety, and Apathy in Patients with Alzheimer's Disease*. Presented at: Corporate Advisory Board Meeting. 2024 September; Seattle, WA. [Link](#)

Yip O, Bounthavong M. *Association between Social Vulnerability and Opioid Dispensing By Contiguous County in the United States*. Presented at: ISPOR—The Professional Society for Health Economics and Outcomes Research Annual Meeting. 2024 May; Atlanta, GA. [Link](#)

Yip O, Du E, Bounthavong M, Morello Candis. *Clinical Outcome Comparisons between Telehealth Visits and In-person Visits among Veterans Referred to a Pharmacist-led Diabetes Management Clinic*. Presented at: American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition . 2023 December; Anaheim, CA. [Link](#)

Yip O, Le BH, Phung KC, Nguyen TH, Nguyen LD, Nguyen ET, Vu HB, Vu HM, Nguyen HLT, Hoang L, Lai H, Le J. *Model-Informed Precision Dosing of Vancomycin in Vietnamese Children: Comparison of Two Bayesian Programs*. Presented at: American College of Clinical Pharmacy. 2023 May; ACCP Virtual Poster Symposium. [Link](#)

Yip O, Bounthavong M. *Is academic detailing on naloxone distribution for patients at risk for an opioid overdose good value for money? Application of a probabilistic sensitivity analysis in a cost-effectiveness framework*. Presented at: ISPOR—The Professional Society for Health Economics and Outcomes Research Annual Meeting. 2023 May; Boston, MA. [Link](#)

Yip O, Bounthavong M. *Cost-Utility Analysis of Academic Detailing Outreach on Naloxone Prescribing for Patients at Risk of Opioid-Related Overdose or Death (Integrated Decision Tree and Markov Models)*. Presented at: ASHP Midyear Clinical Meeting. 2022 December; Las Vegas, NV. [Link](#)

Yip O, Bounthavong M. *Cost-Utility Analysis of Academic Detailing Outreach on Naloxone Prescribing for Patients at Risk of Opioid-Related Overdose or Death (Decision Tree Model)*. Presented at: ISPOR—The Professional Society for Health Economics and Outcomes Research Annual Meeting. 2022 May; Washington, D.C. [Link](#)

Grants and Awards

Louis Sr. and Marilyn Garrison Endowed Prize in Health Policy and Economics

UW CHOICE

AMOUNT: \$700

June 2026

Plein Center for Aging Research Scholarship

Plein Center for Aging

AMOUNT: \$5000; RESEARCH TITLE: COST-UTILITY ANALYSIS OF NON-PRESCRIPTION OSELTAMIVIR

May 2025

Summer Research Program (SRP)

UCSD

AMOUNT: \$5000; RESEARCH TITLE: COST-UTILITY ANALYSIS OF ACADEMIC DETAILING OUTREACH ON NALOXONE

Septemeber 2022

ISPOR Student Conference Grant

ISPOR

INCLUDES REGISTRATION TO VIRTUAL ISPOR EUROPE 2022, 8 HOURS OF SHORT COURSES, AND 1-YEAR OF MEMBERSHIP

August 2022

American Foundation for Pharmaceutical Education Gateway to Research Award

*American Foundation for
Pharmaceutical Education (AFPE)*

AMOUNT: \$5000; RESEARCH TITLE: COST-UTILITY ANALYSIS OF ACADEMIC DETAILING OUTREACH ON NALOXONE

June 2022